<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fibroblast growth factor receptor 2 (FGFR2) is considered a novel therapeutic target for various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We used a silencing strategy to clarify the effect of reduced FGFR2 expression in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cells </plain></SENT>
<SENT sid="2" pm="."><plain>The invasive front of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells exhibited stronger FGFR2 expression than the surface area of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>FGFR2 shRNA-transfected LoVo cells inhibited cell migration, invasion and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in vitro and in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, FGFR2 plays important roles in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> progression in association with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor cell migration</z:e>, invasion and growth, and FGFR2 might be a novel therapeutic target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>